Clinical Evaluation of a Recombinant Factor VIII Preparation (Kogenate) in Previously Untreated Patients with Hemophilia A

International Journal of Hematology

Volumn 78, Issue 5, 2003, Pages 467-474

  Yoshioka, A ^a   Fukutake, K ^b   Takamatsu, J ^c   Shirahata, A ^d  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Antibody to foreign protein; Clinical study; Inhibitor; Kogenate; Previously untreated patients with hemophilia A; Recombinant factor VIII

Indexed keywords

BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 INHIBITOR; IMMUNOGLOBULIN G ANTIBODY; PROTEIN ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ADOLESCENT; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; BLEEDING; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; FOLLOW UP; HEMOPHILIA A; HEMOSTASIS; HUMAN; INFANT; JAPAN; LABORATORY TEST; OUTCOMES RESEARCH; SEROCONVERSION; SIDE EFFECT; SINGLE DRUG DOSE;

EID: 0347479236     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02983823     Document Type: Article

References (24)

1. Gitschier J, Wood WI, Goralka TM, et al. Characterization of the human factor VIII gene. Nature. 1984;312:326-330.
2. Wood WI, Capon DJ, Simonsen CC, et al. Expression of active human factor VIII from recombinant DNA clones. Nature. 1984;312:330-337.
3. Schwartz RS, Abildgaard CF, Aledort LM, et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A: Recombinant Factor VIII Study Group. N Engl J Med. 1990;323:1800-1805.
4. Yoshioka A. Advances in hemophilia and other coagulation disorders: recombinant factor VIII preparations. Int J Pediatr Hematol Oncol. 1994;1:491-497.
5. Fukui H, Yoshioka A, Shima M, et al. Clinical evaluation of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A. Int J Hematol. 1991;54:419-427.
6. Fukui H, Mori K, Ishikawa M, et al. A long-term, multi-center clinical study of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A [in Japanese]. Nihon Yuketsu Gakkai Zasshi. 1991;37:593-604.
7. Kasper CK, Aledort LM, Counts RB, et al. A more uniform measurement of factor VIII inhibitors [letter]. Thromb Diath Haemorrh. 1975;34:869-872.
8. Shima M, Sawamoto Y, Nakai H, et al. Measurement of anti-factor VIII IgG, IgG4 and IgM alloantibodies in previously untreated hemophilia A patients treated with recombinant factor VIII: Kogenate Japanese Clinical Study Group. Int J Hematol. 1995;62:35-43.
9. McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao AV, Lazerson J. The natural history of factor VIII inhibitors in patients with hemophilia A: a national cooperative study, II: observations on the initial development of factor VIII:C inhibitors. Blood. 1988;71:344-348.
10. Sultan Y. Prevalence of inhibitors in a population of 3435 hemophilia patients in France: French Hemophilia Study Group. Thromb Haemost. 1992;67:600-602.
11. Rosendaal FR, Nieuwenhuis HK, van den Berg HM, et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands: Dutch Hemophilia Study Group. Blood. 1993;81:2180-2186.
12. Schwarzinger I, Pabinger I, Korninger C, et al. Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor VIII concentrates. Am J Hematol. 1987;24:241-245.
13. Colvin BT, Hay CRM, Hill FGH, Preston FE. The incidence of factor VIII inhibitors in the United Kingdom, 1990-93: Inhibitor Working Party. United Kingdom Haemophilia Centre Directors Organization. Br J Haematol. 1995;89:908-910.
14. Shima M. Mechanism of the inhibitor development and management in patients with hemophilia [in Japanese]. Nihon Shouni Ketsueki Gakkai Zasshi. 1999;13:399-409.
15. Abe T, Igata A, Ikematsu S, et al. Multcenter clinical effect of heat-treated factor VIII (CP-8) preparation for patients with hemophilia A [in Japanese]. Rinshio to Kenkyu. 1985;62:3640-3659.
16. Fujimaki M, Tanaka A, Fukutake K, et al. Clinical evaluation of recombinant factor VIII (BL-160) in patients with hemophilia A [in Japanese]. Nihon Kessen Shiketsu Gakkaishi. 1993;4:179-188.
17. Fujimaki M, Goto M, Miyazaki T, et al. Clinical study of FVIII concentrate highly purified by monoclonal antibodies to FVIII(RCG-11) [in Japanese]. Kiso to Rinsho. 1992;26:299-319.
18. Shima M. Hemophilia [in Japanese]. Rinshoui. 2001;27:801-806.
19. Scharrer I, Bray GL, Neutzing O. Incidence of inhibitors in haemophilia A patients: a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia. 1999;5:145-154.
20. Lusher JM, Arkin S, Hurst D. Recombinant FVIII (Kogenate) treatment of previously untreated patients (PUPs) with hemophilia A: update of safety, efficacy, and inhibitor development after seven study years. Thromb Haemost. 1997;77(suppl):162-163.
21. Gruppo R, Bray GL, Schroth P, Perry M, Gemperts ED. Safety and immunogenicity of recombinant factor VIII (Recombinate™) in previously untreated patients (PUPs): a 6.5 year update. Thromb Haemost. 1997;77(suppl):162.
22. Addigo JE, Gomperts E Jr, Liu SL, et al. Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIc immunoaffinity chromatography. Thromb Haemost. 1992;67:19-27.
23. Lusher JM. Viral safety and inhibitor development associated with monoclonal antibody-purified FVIII C. Ann Hematol. 1991;63:138-141.
24. Ingerslev J, Christiansen K, Ravn HB, Bray GL, Gomperts ED. Antibodies to heterologous proteins in hemophilia A patients receiving recombinant factor VIII (Recombinate). Thromb Haemost. 2002;87:626-634.